EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia ,

ISSN 2394-3211

Impact Factor: 7.065

ICV - 79.57

Abstract

THE TREATMENT OF REFRACTORY NEPHROTIC SYNDROME IN CHILDREN

Liang Zhao and Hongzhu Lu.*

ABSTRACT

Idiopathic nephrotic syndrome is the commonest chronic kidney disease in children. Most of them are response to steroid treatment. However, about 20% patients are frequently relapse, steroid-dependent, or steroid-resistant nephrotic syndrome. These patients need immune-superresion agents, such as cyclophosphamide, calcineurin inhibitors, or mycophenolate motifol to maintain completely remission. Recently, rituximab used to treat refractory nephrotic syndrome as well. The selection of the drug should be carefully consider according to the disease condition and patients family.

Keywords: nephrotic syndrome; cyclophosphamide; calcineurin inhibitor; mycophenolate motifol; rituximab.

[Full Text Article] [Download Certificate]